<DOC>
	<DOC>NCT02687347</DOC>
	<brief_summary>The research hypothesis of this study is: In patients with moderate to severe cancer related pain, the addition of low dose methadone to an existing opioid significantly reduces pain severity compared to low doses morphine.</brief_summary>
	<brief_title>Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain, Intractable</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Patients diagnosed of cancerrelated pain of more than 3 months duration Pain relief during the last week rated unsatisfactory by the patient Pain severity during the last week rated moderate (between 4 and 7/10) Analgesic therapy must have been stable for 7 days Able to understand English or French Willing and able to give written informed consent Patients who are currently receiving or have received methadone as analgesic in the last 6 months Contraindication to receive methadone (allergy, QTc segment on the ECG&gt;450msec, concurrent treatment with medication that could increase methadone's effects) Patients presenting with changes in their cancer status/treatment with potential effects on their pain severity, during the duration of the trial (eg: new metastasis, indication for radiotherapy) Patients whose life expectancy is shorter than 2 months Patients with cognitive impairment presenting with difficulties understanding the trial and completing the research questionnaires Pregnant or lactating women (women of childbearing potential must have negative pregnancy test)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>